✓ Bengaluru
✓ ZCCK Registered
✓ ZCCK Registered
Acute pancreatitis can range from a few days in hospital to life-threatening necrosis requiring ICU care and complex drainage. Chronic pancreatitis causes progressive pain, malabsorption, and diabetes. Both conditions require specialist HPB management — not just general surgery or gastroenterology.
Acute pancreatitis is sudden inflammation of the pancreas caused by premature activation of digestive enzymes within the gland. In India, the two most common causes are gallstones (40–50%) and alcohol (30–35%). Other causes include high triglycerides (above 1000 mg/dL), medications, ERCP, trauma, and autoimmune disease.
In severe acute pancreatitis, pancreatic tissue dies (necrosis) and fluid collections form. The Atlanta classification (revised 2012) describes four types:
| Type | Timing | Contents | Treatment |
|---|---|---|---|
| Acute Peripancreatic Fluid Collection (APFC) | <4 weeks | Fluid only | Usually resolves spontaneously |
| Pancreatic Pseudocyst | >4 weeks | Fluid, encapsulated | Drain if symptomatic |
| Acute Necrotic Collection (ANC) | <4 weeks | Fluid + necrosis | Drain if infected |
| Walled-Off Necrosis (WON) | >4 weeks | Encapsulated necrosis | Step-up drainage/necrosectomy |
Chronic pancreatitis is progressive, irreversible inflammation and fibrosis of the pancreas leading to loss of both exocrine function (enzyme production — digestion) and endocrine function (insulin — diabetes). In India, the causes are distinct from Western countries:
| Cause | India Prevalence | Notes |
|---|---|---|
| Alcohol-related | 35–40% | Dose-dependent; genetic susceptibility |
| Tropical/Fibrocalculous | 20–25% | Young non-alcoholic; South India, Karnataka; SPINK1 mutation |
| Idiopathic | 20–25% | No identifiable cause; may have genetic component |
| Hereditary | 5–10% | PRSS1, SPINK1, CFTR mutations; high cancer risk |
| Autoimmune (AIP) | <5% | IgG4-related; responds to steroids; must distinguish from cancer |
| Obstructive | <5% | Stricture, pancreas divisum, trauma |
Also called fibrocalculous pancreatic diabetes (FCPD). Affects young, non-alcoholic individuals — typically teenagers and young adults in South India (Karnataka, Kerala, Tamil Nadu). Caused by a combination of malnutrition, genetic susceptibility (SPINK1, CFTR mutations), and possibly cassava toxin. Features: massive intraductal calcification, severe abdominal pain, pancreatic exocrine failure, and a very high risk of pancreatic cancer (50–100× baseline). Annual CA 19-9 and CT surveillance is essential.
Caused by mutations in PRSS1 (cationic trypsinogen), SPINK1 (serine protease inhibitor), or CFTR genes. Presents in childhood or early adulthood with recurrent acute pancreatitis progressing to chronic disease. Lifetime pancreatic cancer risk is 40–55% in PRSS1 mutation carriers. Genetic testing is recommended in patients with chronic pancreatitis below age 25, family history of pancreatitis, or suspected hereditary pattern. Endoscopic and surgical treatments are the same as other forms.
IgG4-related disease that causes diffuse pancreatic enlargement and obstructive jaundice — often misdiagnosed as pancreatic cancer. Critical distinction: AIP responds dramatically to steroid treatment within 2–4 weeks; pancreatic cancer does not. Features suggesting AIP: diffuse sausage-shaped pancreas, absence of vascular invasion, elevated serum IgG4, extrapancreatic IgG4 manifestations (sclerosing cholangitis, retroperitoneal fibrosis). Do not operate for AIP before a steroid trial.
Identify the aetiology — biliary vs alcohol vs tropical vs autoimmune vs hereditary. MRCP, EUS, genetic testing, and IgG4 levels as clinically indicated. Accurate cause determines treatment strategy.
BISAP, CTSI, CRP at 48 hours, organ function monitoring. Early aggressive IV fluid resuscitation (4–6 litres in first 24 hours with lactated Ringer's) is the most evidence-backed intervention. HDU/ICU referral for predicted severe pancreatitis.
Biliary pancreatitis: cholecystectomy before discharge or within 2 weeks. Alcohol-related: structured alcohol cessation support. Hypertriglyceridaemia: aggressive lipid control (fibrates, omega-3). Hereditary/tropical: genetic counselling.
Nutritional optimisation, enzyme replacement, diabetes control. Early surgical referral when duct is dilated and pain is refractory — surgery before opioid dependency develops gives better outcomes.
For hereditary and tropical pancreatitis: annual CT abdomen + CA 19-9 from age 40 (or 20 years after diagnosis). Chronic pancreatitis and new-onset diabetes after age 50 should also be evaluated to exclude pancreatic cancer.
Acute pancreatitis is a sudden attack of pancreatic inflammation — most commonly from gallstones or alcohol. In 80% of cases it resolves within a week with supportive treatment and the pancreas returns to normal. In 20%, it is severe, causing necrosis and organ failure requiring ICU care. Chronic pancreatitis is a different condition — long-term irreversible scarring of the pancreas that develops over years of repeated attacks or ongoing inflammation. It causes constant pain, malabsorption (floating stools, weight loss), and diabetes. The two conditions have different treatments, though they share causes and some patients progress from recurrent acute to chronic disease.
Yes — and timing matters. After mild biliary pancreatitis (most common), cholecystectomy (gallbladder removal) should be done during the same hospital admission or within 2 weeks of discharge. Without cholecystectomy, the risk of a second episode of biliary pancreatitis is 30–50%, and the second attack is often more severe. For severe pancreatitis, the acute inflammation must settle first (usually 4–6 weeks), then elective cholecystectomy is planned. ERCP is done urgently only if there is ongoing bile duct obstruction. Do not leave the hospital with gallstones without a clear plan for cholecystectomy.
Pancreatic necrosis occurs in severe acute pancreatitis when portions of the pancreatic tissue die due to lack of blood supply. Sterile necrosis — with no infection — can often be managed without intervention if the patient stabilises. Surgery or drainage is needed when: necrosis becomes infected (fever, rising CRP despite antibiotics, gas bubbles in CT), when there is ongoing organ failure from the necrosis itself, or when large collections are causing problems. Modern management uses the 'step-up approach': starting with the least invasive drainage (percutaneous CT-guided drainage or endoscopic transmural drainage), escalating to minimally invasive necrosectomy only if needed. Open surgery is a last resort — it is reserved for cases where minimally invasive approaches have failed.
A pseudocyst is a sac of fluid that develops after acute pancreatitis or in chronic pancreatitis, caused by disruption of the pancreatic duct with fluid leaking into a cavity surrounded by fibrous tissue (not a true cyst lining). Small pseudocysts (under 4 cm) often resolve spontaneously over weeks — no intervention needed. Treatment is indicated when: the pseudocyst is large and causing symptoms (persistent pain, nausea, early satiety from gastric compression), growing on serial imaging, becoming infected (abscess), causing biliary obstruction or jaundice, or rupturing (rare). Modern treatment is EUS-guided transgastric drainage — a gastroenterologist passes an endoscope and creates a drain from stomach to the cyst. This replaces open surgery in most cases.
Yes — and surgery often provides better long-term pain control than repeated endoscopic procedures. The key condition for surgical eligibility: a dilated main pancreatic duct (above 5 mm on MRCP or CT). If the duct is dilated, the Frey or Puestow procedure creates a large drainage connection between the duct and intestine, relieving the obstructive component of the pain. If there is also an inflammatory mass in the pancreatic head (common in alcohol-related chronic pancreatitis), the Frey procedure also cores out the head. Two large randomised trials showed surgery gives better long-term pain relief than endoscopy for chronic pancreatitis. Surgery should be considered earlier — not as a last resort after years of failed procedures and opioid dependency.
Tropical pancreatitis (also called fibrocalculous pancreatic diabetes or FCPD) is a unique form of chronic pancreatitis found in South and Southeast Asia and parts of Africa. It predominantly affects young, non-alcoholic individuals — often in their teens and twenties — in South India, including Karnataka. The hallmark is massive calcification of the pancreatic duct visible on plain X-ray and CT, combined with severe exocrine and endocrine insufficiency. Genetic mutations (SPINK1, CFTR) are frequently found. The most important clinical concern is the extremely elevated pancreatic cancer risk — 50 to 100 times higher than the general population. Annual surveillance with CT and CA 19-9 is essential from the time of diagnosis.